Currently, an estimated 44 million people are affected by dementia worldwide, and an estimated 7.7 million new cases are diagnosed each year. The prevalence doubles every five years beyond the age of 65. The number of people affected by dementia is expected to be over 75 million in 2030, and 135 million in 2050. Alzheimer’s disease (AD) is the most common cause of dementia among older people, accounting for 60-70% of all cases. It is the sixth-leading cause of death in the United States.
Dementia and Alzheimer’s disease might be potentially manifested through prolonged stress in the brain, which causes protein misfolding. In this situation the brain might not able to fend off the protein misfolding that could accumulate over time. The very high correlation of Alzheimer’s with age speaks to the manifestation of some constant aggression and probably the domino effect of this protein misfolding. The chronic distress in the brain might have many sources. It could be caused by genetic factors, anxiety, lack of regular sleep, lack of physical exercise, and poor diet. For example, we know today that all the things that are bad for the heart are also bad for the brain. The chronic cell stress eventually might cause the aggregation of Abeta or Tau, the characteristic of many Alzheimer’s patients.
Despite the huge need, there are currently only a few FDA-approved Alzheimer’s drugs that only treat the symptoms. However, they do not treat the underlying causes of the disease, and sadly, there are no treatments to stop or reverse the progression.
We, at Anavex, are driven to find a potential solution to dementia and Alzheimer’s disease. Our Company has made important advances in the past year- from presenting successful Phase 1 data for the Company’s lead drug candidate, ANAVEX 2-73 , to initiating a Phase 2a clinical trial of ANAVEX 2-73 for the potential treatment of Alzheimer’s disease.
Findings in a recent peer-reviewed scientific journal reveals that our lead drug, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.
Our approach targets dementia and Alzheimer’s disease further upstream and apparently blocks the disease hallmarks.
Hence, our drugs might be possibly targeting the underlying cause of the disease.
Please follow the progress of our Phase 2a trial for the potential treatment of Alzheimer’s. We are expecting preliminary data from the ongoing study in the third quarter of 2015, and we are working towards a positive outcome in order to provide relief to all those affected by this terrible disease.